Prevention of cyclophosphamide-induced ovarian damage by concomitant administration of GnRHa in mice

Basit Öğe Kaydı
dc.authoridCanda, M. Tunc/0000-0001-6348-4493
dc.authorwosidCanda, M. Tunc/ABC-5001-2020
dc.contributor.authorYüce, MA
dc.contributor.authorKaplan, PB
dc.contributor.authorGücer, F
dc.contributor.authorDoganay, L
dc.contributor.authorAltaner, S
dc.contributor.authorCanda, T
dc.contributor.authorYardim, T
dc.date.accessioned2024-06-12T10:56:14Z
dc.date.available2024-06-12T10:56:14Z
dc.date.issued2004
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective (s): This experimental study investigates the dose-related effects of cyclophosphamide (Cy) on primordial follicular reserve in young mice, and examines whether the concomitant administration of a gonadotropin-releasing hormone agonist (GnRHa) may protect gonadal reserve, even at different doses of Cy. Methods: Forty sexually mature virginal Balb/c mice aged five to six weeks were administered different doses (0, 50, 75,100 mg/kg) of Cy. Another 40 animals were treated with increasing doses (10, 50, 75, 100 mg/kg) of Cy in combination with GnRHa. GnRHa treatment was initiated one week prior to chemotherapy and also continued after chemotherapy for one week. The ovaries were removed seven days after Cy administration and the total number of primordial follicles in both ovaries was counted. Results: Primordial follicular destruction occurred at all levels of Cy exposure. There was a positive correlation between increasing doses of Cy and higher proportion of follicular loss (p < 0.0001). GnRHa was not able to protect against the chemotherapy-induced negative effect on primordial follicular count at low doses (50 mg/kg and 75 mg/kg). Mean +/-SD primordial follicle count in the 100 mg/kg Cy-treated group was significantly lower than in the 100 mg/kg Cy + GnRHa treatment group (73.9 +/- 33.1 vs 89 +/- 17.9, p = 0.047). Conclusion: Our data suggest a possible ovarian protective effect of GnRHa cotreatment only at high doses of Cy treatment. However, in spite of co-administration of GnRHa, loss of primordial follicular reserve occurred at all doses of Cy in mice.en_US
dc.identifier.endpage631en_US
dc.identifier.issn0392-2936
dc.identifier.issue5en_US
dc.identifier.pmid15493183en_US
dc.identifier.startpage628en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19707
dc.identifier.volume25en_US
dc.identifier.wosWOS:000224169800022en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherI R O G Canada, Incen_US
dc.relation.ispartofEuropean Journal Of Gynaecological Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemotherapyen_US
dc.subjectGnrha-1 Ovarian Toxicityen_US
dc.subjectPremature Ovarian Failureen_US
dc.subjectPrimordial Folliclesen_US
dc.subjectCyclophosphamideen_US
dc.subjectPrimordial Follicular Reserveen_US
dc.subjectGonadotropin-Releasing Hormoneen_US
dc.subjectPrimordial Follicular Reserveen_US
dc.subjectPreserve Fertilityen_US
dc.subjectHodgkins-Diseaseen_US
dc.subjectChemotherapyen_US
dc.subjectCanceren_US
dc.subjectFailureen_US
dc.subjectAgonisten_US
dc.subjectCombinationen_US
dc.subjectProtectionen_US
dc.titlePrevention of cyclophosphamide-induced ovarian damage by concomitant administration of GnRHa in miceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu